

Research Department research@alrajhi-capital.com

Tel: +966 11 836 546

### **Major Indices**

	Close	1D%	WTD%	YTD%
Regional Indices				
TASI	10,899	-0.3	-0.3	-9.4
MT30	1,406	0.0	0.0	-6.7
DSM	11,362	0.0	0.0	7.5
KSE	9,320	0.6	0.6	18.9
ADSM	10,312	0.0	0.0	9.5
DFM	6,149	0.0	0.0	19.2
MSM30	4,856	0.1	0.1	6.1
BSE	1,944	0.0	0.0	-2.1
MSCI GCC	749	0.0	0.0	3.6
Global Indices				
DJ Industrial	44,176	0.0	0.0	3.8
S&P 500	6,389	0.0	0.0	8.6
Nasdaq	21,450	0.0	0.0	11.1
FTSE 100	9,096	0.0	0.0	11.3
DAX	24,163	0.0	0.0	21.4
CAC 40	7,743	0.0	0.0	4.9
Nikkei 225	41,820	0.0	0.0	4.8
Hang seng	24,859	0.0	0.0	23.9
Kospi	3,210	0.0	0.0	33.8
Shanghai Composite	3,635	0.0	0.0	8.5
ASX 200	4,939	0.0	0.0	10.6
Sensex	79,858	0.0	0.0	2.2
MSCI World	4,125	0.0	0.0	11.3
MSCI EM	1,254	0.0	0.0	16.6

### **Major Commodities and Currencies**

	Close	1D %	1D % WTD %	
Commodities				
Brent Crude (\$/bbl)	66.59	0.0	0.0	-7.9
WTI Crude (\$/bbl)	63.88	0.0	0.0	-7.6
Natural Gas (\$mmbtu)	2.99	0.0	0.0	-15.6
Gold Spot (\$/Oz)	3,397.75	0.0	0.0	29.5
Silver Spot (\$/Oz)	38.34	0.0	0.0	32.7
Steel (\$/ton)	835.00	0.0	0.0	17.8
Iron Ore (CNY/MT)	790.00	0.0	0.0	4.9
Copper (\$/MT)	9,692.45	0.0	0.0	12.0
Zinc (\$/MT)	2,826.77	0.0	0.0	-4.3
Currencies				
Dollar Index	98.18	0.0	0.0	-9.5
Euro	0.86	0.0	0.0	11.1
Japanese Yen	147.74	0.0	0.0	6.0
Sterling Pound	0.74	0.0	0.0	7.0
Chinese Yuan	7.19	0.0	0.0	2.0

Data Sources: Bloomberg

# **Global commentary**

- Investors await key US data this week, with July CPI (YoY) due Tuesday, and July Retail Sales (MoM) and August Michigan Consumer Sentiment Index due Thursday (Source: Fxstreet).
- In Europe, UK July Claimant Count Change and June ILO Unemployment Rate (3M) are due Tuesday; Germany's July Harmonized CPI (YoY) is due Wednesday; UK Q2 GDP (QoQ) and Eurozone Q2 GDP s.a. (YoY) are due Thursday (Source: Fxstreet).
- Asia-Pacific markets traded subdued Monday as investors awaited confirmation on whether the Aug. 12 US-China tariff truce deadline will be extended (Source: CNBC).
- Oil prices fell in early Asian trade Monday, extending last week's 4% drop, pressured by higher US tariffs, an OPEC output hike, and expectations of a potential US-Russia Ukraine ceasefire pact (Source: Reuters).
- **Gold** retreated from Friday's record high after the White House said it would clarify "misinformation" regarding tariffs on the precious metal (Source: CNBC).

### **Economic Calendar**

Date	Economic Indicator	Actual	Consensus	Previous
12-Aug	UK Claimant Count Change (Jul)	-	20.8K	25.9K
12-Aug	UK ILO Unemployment Rate (3M) (Jun)	-	4.7%	4.7%
12-Aug	US Consumer Price Index (YoY) (Jul)	-	2.8%	2.7%
13-Aug	GER Harmonized Index of Consumer Prices	-	1.8%	1.8%
14-Aug	UK Gross Domestic Product (QoQ) (Q2)	-	0.1%	0.7%
14-Aug	EUR Gross Domestic Product s.a. (YoY) (Q2)	-	1.4%	1.4%
15-Aug	US Retail Sales (MoM) (Jul)	-	0.5%	0.6%
15-Aug	US Michigan Consumer Sentiment Index (Aug)	-	62.1	61.7

Data Sources: Al Rajhi Capital and FXStreet.

## **Interest Rates**

	1M	3M	12M	3M Chg (YoY)
SOFR	4.34	4.34	-	-1.02
SAIBOR	5.76	5.35	5.21	-0.84
EIBOR	4.37	4.19	4.13	-0.90

Data Sources: Bloomberg Note: SOFR Rate for 12M is not available Updated as of 11/Aug/2025 7:50 AM



# Saudi commentary

- The Tadawul All Share Index (TASI) fell 0.29% to close at 10,899.11. Eighteen of the twenty-one sector indices declined, led by Media & Entertainment (-2.1%) and Consumer Services (-1.7%). Telecommunication Services (+0.8%) and Pharma, Biotech & Life Science (+0.5%) topped the gainers. The advance-decline ratio was 77/169, with total trading turnover at SAR 3.5bn.
- National Medical Care Co. (Care) secured final MOH approval to increase Care Medical Al Rawabi Hospital's bed capacity to 360 from the current 325 (Source: Tadawul).
- **Saudi ports** handled 722,500 tons of cargo in July, up 12% y-o-y (Source: Tadawul).
- Scientific and Medical Equipment House Co.'s board recommended a 10% cash dividend, equivalent to SAR 1 per share, for 2024 (Source: Argaam).
- **flynas** posts SAR 714.6M loss in H1 2025; Q2 loss widens to SAR 862.5M on non-recurring items (Source: Tadawul).
- Al Mawarid H1 2025 profit rises 25.5% YoY to SAR 62.3M;
  Q2 at SAR 32.4M (Source: Tadawul).


## **Corporate events**

• Today is the ex-dividend date of Jarir, Aldawaa, and Alkhabeer REIT.

## **Sector Indices**

Index	1D %	WTD %	YTD %
Energy	-0.8	-0.8	-13.6
Materials	0.0	0.0	-7.2
Capital Goods	-0.7	-0.7	-1.0
Commercial	-0.1	-0.1	-8.3
Transportation	-0.1	-0.1	-18.9
Consumer Durables	-1.7	-1.7	-9.1
Consumer Services	-1.7	-1.7	-11.6
Media	-2.1	-2.1	-37.0
Retailing	-0.1	-0.1	-0.7
Food & Staples	-0.4	-0.4	-11.6
Food & Beverages	-0.2	-0.2	-19.4
Health Care	-0.2	-0.2	-9.0
Pharma	0.5	0.5	-4.5
Diversified Financials	-0.4	-0.4	-17.8
Software & Services	-0.3	-0.3	-16.0
Real Estate	-0.7	-0.7	-5.4
Insurance	-0.3	-0.3	-20.7
REIT	-0.5	-0.5	-6.2
Banks	-0.2	-0.2	-1.3
Telecom	0.7	0.7	9.4
Utilities	-0.1	-0.1	-39.6
Data Sources: Bloomberg	,		

#### TASI - Price & Turnover - 3-Month Trend



### **TASI - Gainers and Losers**

Company	Last Price	Chg %	Vol (mn)	Value Trd (SAR mn)
Top Gainers				
Red Sea	42.24	10.0	0.7	30.7
Tamkeen	57.10	7.9	0.5	31.0
Saudi Re	47.66	5.9	1.1	50.3
TECO	1.02	4.1	71.0	71.5
TALCO	42.40	4.0	0.2	10.0
Top Losers				
Jahez	25.02	-10.0	5.4	135.4
Alarabia	87.35	-10.0	8.0	71.7
Lazurde	12.10	-6.8	0.3	3.1
SIIG	18.24	-6.7	1.2	22.4
Tanmiah	87.40	-6.1	0.2	17.0

### TASI - Stocks Closer to 52 Week High/Low

Company	Last Price	52Wk High/Low	Diff %	Value Trd (SAR mn)
52 Week High				
SABIC Agri-Nutrients	119.60	122.60	2.5	30.9
Etihad Etisalat	62.75	64.50	2.8	30.5
SISCO Holding	35.50	36.70	3.4	45.6
Albabtain	58.60	60.90	3.9	71.4
SNB	36.20	37.72	4.2	74.1
52 Week Low				
Alandalus	18.28	18.28	0.0	1.6
Alarabia	87.35	87.35	0.0	71.7
YCC	16.70	16.67	0.2	18.4
MCDC	78.70	78.55	0.2	7.1
Savola Group	24.12	24.06	0.2	10.9

## **TASI - Heavy Weight Stocks**

Company	Last Price	Chg %	Index Imp	Value Trd (SAR mn)
Saudi Aramco	24.14	-0.8	-15.4	234.3
Al Rajhi	94.80	-0.5	-8.9	89.2
ACWA Power	218.10	0.3	1.5	42.7
SNB	36.20	0.6	4.0	74.1
STC	42.62	1.1	4.8	90.1

## **TASI - Most Active by Value Traded**

	Last	Chg	Vol	Value Trd
Company	Price	%	(mn)	(SAR mn)
Saudi Aramco	24.14	-0.8	9.7	234.3
Sport Clubs	12.67	-1.4	13.0	165.9
Jahez	25.02	-10.0	5.4	135.4
Alinma	25.78	-1.4	4.3	111.6
Maaden	53.45	2.4	1.9	100.4
Data Sources: Bloomberg				



# **SUMMARY OF OUR COVERAGE**

	Mcap				EV/EBITDA (x)		
	(SARmn)	Price	2025E	2026E	2025E	2026E	
Petchem							
SABIC	172,050	57.4	28.2x	18.1x	7.4x	6.0x	
Sipchem	13,669	18.6	7.8x	7.1x	5.9x	5.5x	
SABIC Agri-Nutrients	56,934	119.6	13.7x	12.4x	9.1x	8.4x	
Yansab	18,146	32.3	40.0x	22.8x	8.7x	7.0x	
Advanced	8,294	31.9	15.9x	12.7x	24.1x	20.2x	
Building construction							
ACC	2,165	21.7	19.2x	16.9x	9.1x	8.6x	
YC	6,950	34.3	16.5x	14.0x	15.7x	14.1x	
Saudi Cement	5,936	38.8	14.3x	13.4x	9.7x	9.3x	
QACCO	4,999	45.2	17.0x	13.9x	15.5x	13.0x	
YCC	2,630	16.7	18.0x	14.6x	8.6x	8.0x	
SPCC	3,724	26.6	13.2x	14.0x 11.2x	9.5x	8.8x	
		26.6 8.1					
Najran Cement	1,372		13.2x	12.0x	8.4x	8.0x	
Riyadh Cement	3,638	30.3	17.3x	16.3x	10.8x	10.5x	
Bawan	3,546	59.1	24.9x	20.8x	18.4x	16.9x	
Riyadh Cables	20,730	138.2	19.7x	17.6x	16.8x	15.2x	
Marble Design	443	7.4	1.4x	1.3x	12.2x	11.3x	
Saudi Ceramics	3,100	31.0	21.1x	15.0x	15.2x	12.5x	
Геlесот							
STC	213,100	42.6	14.5x	13.9x	8.0x	7.7x	
Etihad Etisalat	48,318	62.8	14.1x	13.1x	7.1x	6.7x	
Zain KSA	9,661	10.8	11.9x	10.8x	5.5x	5.3x	
Food & Agriculture							
Almarai	47,700	47.7	18.9x	16.4x	10.3x	9.5x	
Savola Group	7,236	24.1	12.6x	11.9x	5.3x	5.2x	
SADAFCO	8,905	274.0	17.6x	17.1x	13.2x	12.9x	
NADEC	6,371	21.1	13.2x	12.9x	7.3x	6.5x	
Almunajem	3,930	65.5	15.4x	13.2x	14.4x	12.6x	
First Mills	3,030	54.6	12.4x	16.3x	11.9x	13.7x	
Modern Mills	2,615	32.0	11.9x	15.1x	10.7x	12.4x	
Tanmiah	1,748	87.4	16.8x	14.7x	7.5x	6.8x	
Entaj	1,250	41.7	14.7x	11.2x	7.3x	6.2x	
D-4-11							
<b>Retail</b> Iarir	15,564	13.0	15.8x	16.7x	13.1x	13.7x	
Cenomi Retail	3,147	27.4	NM	NM	9.6x	8.9x	
A.Othaim Market	6,750	7.5	20.8x	20.8x	9.9x	9.5x	
eXtra	7,192	89.9	14.2x	12.8x	8.7x	7.8x	
BinDawood	6,721	5.9	22.1x	19.9x	9.6x	9.2x	
_eejam Sports	7,491	143.0	22.8x	19.9x	12.1x	10.7x	
Ja a léba a va							
Healthcare	12.055	126.4	22.45	27.49	22.79	20 5	
Dallah Health	13,855	136.4	33.1x	27.1x	23.7x	20.5x	
Mouwasat	15,600	78.0	25.2x	24.8x	16.9x	15.8x	
Care	7,710	171.9	28.7x	26.2x	19.4x	17.8x	
Al Hammadi	5,594	35.0	19.5x	16.9x	14.8x	13.7x	
Saudi German Health	5,403	58.7	17.4x	16.6x	11.0x	10.4x	
akeeh Care	9,280	40.0	26.5x	21.9x	17.8x	14.1x	
Sulaiman Al Habib	92,400	264.0	34.7x	27.2x	28.8x	22.8x	
_ogistics							
SISCO Holding	2,897	35.5	35.5x	26.6x	6.5x	6.0x	
lahez	5,250	25.0	18.1x	14.5x	13.2x	10.7x	
SAL	14,016	175.2	21.8x	19.7x	18.1x	16.3x	



	Mcap	Mcap		P/E (x)		EV/EBITDA (x)	
	(SARmn)	Last Price -	2025E	2026E	2025E	2026E	
nsurance							
Bupa Arabia	22,650	151.0	20.5x	19.0x	NA	NA	
Tawuniya	19,275	128.5	21.1x	18.8x	NA	NA	
GIG	1,290	24.6	13.9x	13.1x	NA	NA	
Malath Insurance	655	13.1	8.6x	7.5x	NA	NA	
Walaa	1,610	12.6	NM	13.7x	NA	NA	
Saudi Re	5,520	47.7	34.5x	30.0x	NA	NA	
	2,222						
Energy							
Saudi Aramco	5,841,880	24.1	15.4x	14.5x	7.1x	6.7x	
Arabian Drilling	6,720	75.5	24.4x	18.9x	6.5x	6.3x	
Aldrees	12,270	122.7	30.1x	26.5x	13.1x	11.7x	
ADES	16,992	15.1	18.8x	15.1x	8.7x	8.1x	
_uberef	15,441	91.5	11.7x	12.9x	9.5x	10.4x	
Т							
MIS	3,894	129.8	34.3x	29.8x	7.1x	6.7x	
Solutions	30,000	250.0	20.4x	17.9x	6.5x	6.3x	
Tam Development	419	114.5	6.1x	5.0x	8.7x	8.1x	
ELM	74,400	930.0	36.9x	30.7x	9.5x	10.4x	
2P	3,246	10.8	15.1x	12.4x	13.9x	11.6x	
Rasan	7,166	92.5	54.7x	38.4x	40.0x	28.2x	
Pharma							
SPIMACO	3,120	26.0	23.2x	18.8x	15.3x	13.9x	
Jamjoom Pharma	11,368	162.4	27.0x	24.3x	22.9x	20.6x	
Avalon Pharma	2,452	122.6	26.3x	22.9x	20.3x	17.8x	
Astra Industrial	11,560	144.5	17.0x	15.2x	16.1x	14.4x	
Transportation and Tourisn	0						
Theeb	2,784	64.8	13.0x	11.7x	6.4x	6.1x	
Budget Saudi	5,644	72.2	14.1x	12.4x	7.1x	6.5x	
_umi	3,361	61.1	15.2x	13.1x	6.9x	6.5x	
Seera	7,674	25.6	26.0x	23.9x	9.4x	8.6x	
Catrion	9,086	110.8	24.6x	20.7x	17.6x	14.7x	
SGS	8,780	46.7	22.2x	17.4x	13.7x	11.4x	
Real Estate							
Al Akaria	7,088	18.9	14.9x	15.0x	10.5x	10.5x	
Cenomi	9,951	21.0	26.5x	14.5x	15.7x	12.8x	
Retal	6,875	13.8	18.3x	15.1x	16.6x	13.8x	
Arriyadh	7,720	33.0	42.9x	38.4x	41.1x	32.6x	
Staffing	0.400	6.0	20.05	20.0	40.0	0.0	
SMASCO	2,400	6.0	20.0x	20.0x	10.2x	9.6x	
Tamkeen	1,513	57.1	16.8x	15.4x	13.0x	12.0x	
Maharah	2,294	4.8	16.1x	12.1x	14.0x	10.8x	
Al Mawarid	1,952	130.1	17.3x	15.0x	11.7x	9.8x	
Others							
adawul Group	20,316	169.3	26.6x	24.1x	22.9x	20.4x	
Al Arabia	4,804	87.4	7.9x	7.3x	3.2x	3.0x	
AWPT	4,522	129.2	17.2x	14.1x	13.0x	11.2x	
ACWA Power	167,172	218.1	54.6x	41.4x	37.3x	31.0x	
AMAK	6,008	66.8	22.3x	20.9x	37.3x 11.7x	13.9x	
Equipment House	1,091	36.4	14.9x	12.5x	11.0x	9.7x	
Miahona	4,216	26.2	48.7x	31.4x	32.0x	30.1x	
Academy of Learning	729	8.1	12.9x	9.4x	9.5x	7.4x	
UIHC	3,920	156.8	16.5x	14.5x	NA	NA	

Source: Bloomberg, AlRajhi Capital Note: For PE and EV/EBITDA multiples, anything above 100 is considered as NM




# **SBL Positions - Top Stocks**

Compony	TSLV	TSLV		Weekly	% of	% of	DTC
Company	(SAR mn)	%	Change (%)	Change (SAR mn)	Mkt Cap	FF	(20 Days)
Saudi Aramco	785.4	22.3	-22.43	(227.0)	0.01	0.07	2.8
Tadawul Group	174.5	5.0	5.33	8.8	0.86	2.15	11.2
ACWA Power	153.9	4.4	3.32	4.9	0.09	0.18	1.6
Jarir	138.9	4.0	-3.03	(4.3)	0.89	0.94	8.5
Dallah Health	129.1	3.7	-0.62	(0.8)	0.93	2.17	17.5
SIPCHEM	128.7	3.7	9.96	11.7	0.94	0.97	5.5
SAL	109.3	3.1	4.63	4.8	0.78	1.53	7.5
Ades	81.2	2.3	26.19	16.9	0.48	1.30	1.6
SIIG	79.6	2.3	27.99	3.6	0.12	0.14	5.4
Alinma	71.5	2.0	5.28	17.4	0.58	0.71	0.6
Saudi Kayan	65.3	1.9	3.72	3.1	0.79	0.84	2.7
Advanced	63.7	1.8	5.14	2.3	0.89	1.37	2.5
Nahdi	63.7	1.8	11.41	6.5	0.40	0.64	3.8
Yansab	63.1	1.8	19.03	10.1	0.35	0.71	4.7
Solutions	57.5	1.6	8.50	4.5	0.19	0.95	3.3
A.Othaim Market	54.6	1.6	3.31	1.7	0.81	1.26	5.9
NADEC	54.1	1.5	4.06	2.1	0.85	1.38	5.0
Americana	53.7	1.5	1.72	0.9	0.30	0.89	1.7
Seera	51.9	1.5	-0.90	(0.5)	0.68	0.74	1.7
Almarai	51.2	1.5	2.34	1.2	0.11	0.11	1.7

Note: TSLV - Total securities on loan value, FF - Free float, DTC - Days to cover, %TSLV represents the TSLV of the stock divided by the Total TSLV.

# Aggregate Sum of Net Short Positions (%)



■% Net Short Positions Over Outstanding Shares

■ % Net Short Positions Over Free Float of Shares

Data Sources: Al Rajhi Capital, Saudi Exchange (Tadawul)

# Weekly ownership data (%)

	4/Jun/25	12/Jun/25	19/Jun/25	26/Jun/25	3/Jul/25	10/Jul/25	17/Jul/25	24/Jul/25	31/Jul/25	7/Aug/25
Saudi Individuals - Retail	1.67	1.65	1.65	1.74	1.69	1.71	1.73	1.74	1.69	1.71
Saudi Individuals - Others	7.95	7.84	7.70	8.07	7.98	7.93	8.00	8.00	7.98	7.97
Saudi Institutions - Corporates	17.38	17.30	17.31	17.56	17.44	17.37	17.45	17.42	17.38	17.43
Saudi Institutions - Mutual Funds	3.19	3.16	3.13	3.27	3.18	3.15	3.19	3.18	3.15	3.14
Saudi Institutions - GREs	64.23	64.56	64.75	63.64	63.54	63.70	63.43	63.46	63.66	63.60
Saudi Institutions - Institution DPMs	0.46	0.45	0.44	0.46	0.86	0.85	0.86	0.84	0.83	0.84
GCC	0.75	0.74	0.73	0.77	0.76	0.76	0.77	0.77	0.76	0.78
Foreign - QFIS	3.51	3.48	3.47	3.61	3.63	3.62	3.65	3.66	3.65	3.64
Foreign - Others	0.85	0.84	0.83	0.87	0.93	0.92	0.92	0.92	0.91	0.89
Total	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Data Sources: Al Rajhi Capital, Saudi Exchange (Tadawul)



### **IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report was prepared by Al Rajhi Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### **Additional Disclosures**

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Rajhi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Rajhi.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.



## Disclaimer and additional disclosures for Equity Research

#### Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

## Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SoTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

# **Contact us**

**Dr. Sultan Altowaim** 

Head of Research Tel: +966 11 836 5468

Email: AltowaimS@alrajhi-capital.sa

#### Al Rajhi Capital

Research Department Head Office, King Fahad Road P.O. Box 5561, Riyadh 11432 Kingdom of Saudi Arabia Email: research@alrajhi-capital.com

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37



### **Notice to US Investors:**

#### **Rule 15a6 Disclosure**

This research report ("Report") was prepared, approved, published, and distributed by Al Rajhi Capital, a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act") may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

## **Analyst Certification**

In connection with the companies or securities that; each analyst identified in this Report certifies that:

The views expressed on the subject companies and securities in this Report reflect their personal views

No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and

Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

## **Important US Regulatory Disclosures on Subject Companies**

Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed



exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <a href="https://aviorcapital.us/us-regulatory-disclosures/">https://aviorcapital.us/us-regulatory-disclosures/</a>, and Investors are strongly encouraged to review this information before investing.

### **Notice to UK Investors:**

This Report, prepared by the Foreign Counterparty, is distributed in the United Kingdom ("UK") by Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), on behalf of the Foreign Counterparty. This Report, including any recommendations in respect thereof, may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned herein may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior UK does not assume any responsibility, or liability of any nature whatsoever, arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

**Avior Capital Markets US, LLC** is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

**Avior Capital Markets International Limited** is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 4th Floor, 17 St Swithin's Lane, London, EC4N 8AL.

Al Rajhi Capital is a Saudi Arabian Registered broad-scoped financial services company. Its registered address is Unit No 1, 8467 King Fahd Road, Al Muruj Dist., Riyadh 12263 – 2743, SA.